Spersallerg

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

Registration

Applicants: 1
Registrations: 1

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Adcock ingram limited	Spersallerg	0.5 mg /1 ml	H1283	Not determined	PI PIL

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Spersallerg EACH 100 ml CONTAINS ANTAZOLINE HYDROCHLORIDE A 0,05 g TETRAHYDROZOLINE HYDROCHLORIDE A 0,04 g	0.5 mg /1 ml.Sterile eye drops	H1283Approved 21 February 2022	Old Medicine	Not determined	PI PIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

S2: Antazoline
Consolidated Schedules 06 July 2026, line 1590
S2: Tetrahydrozoline
- except when intended for nasal use.
Consolidated Schedules 06 July 2026, line 2717
S1: Tetrahydrozoline
- when intended for nasal use.
Consolidated Schedules 06 July 2026, line 1106

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading Wikipedia summary

SAHPRA documents

Professional information (PI)For healthcare professionalsSpersallerg, Adcock ingram limited Patient information leaflet (PIL)For patients and carersSpersallerg, Adcock ingram limited

These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles